News - Valeant Pharmaceuticals, Dermatologicals

Filter

Popular Filters

Valeant Pharma to sell filler and toxin assets to Nestle for $1.4 billion

Valeant Pharma to sell filler and toxin assets to Nestle for $1.4 billion

28-05-2014

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into an agreement to…

DermatologicalsGaldermaMergers & AcquisitionsNestlePharmaceuticalValeant Pharmaceuticals

Valeant spending $475 million to boost dermatology portfolio

Valeant spending $475 million to boost dermatology portfolio

03-02-2014

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into a definitive agreement…

DermatologicalsMergers & AcquisitionsPharmaceuticalPreCision DermatologyValeant Pharmaceuticals

Regulatory briefs: Gilead files sofosbuvir; FDA approves Diclegis; Health Canada clears Dysport

09-04-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) says it has submitted a New Drug Application to the US…

Anti-viralsBiotechnologyDermatologicalsDiclegisDuchesnayDysportGilead SciencesIpsenNorth AmericaPharmaceuticalRegulationsofosbuvirValeant PharmaceuticalsWomen's Health

Valeant to acquire Obagi Medical for around $344 million

20-03-2013

Canada-based Valeant Pharmaceuticals International (TSX: VRX) is on the acquisition trail again, announcing…

DermatologicalsMergers & AcquisitionsObagi Medical ProductsPharmaceuticalValeant Pharmaceuticals

Valeant on the prowl again, with bid to buy Medicis for about $2.6 billion

04-09-2012

In a sixth acquisition so far this year, as well as several takeovers the previous year, Canada's Valeant…

DermatologicalsMedicis PharmaceuticalMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

US FTC updates on Valeant dermatology acquisitions

23-02-2012

Following public comment periods for both transactions, the US Federal Trade Commission has approved…

DermatologicalsMarkets & MarketingPharmaceuticalValeant Pharmaceuticals

FTC stipulates divestments for Valeant acquisitions

14-12-2011

Canada’s Valeant Pharmaceuticals International (TSX: VRX) has been ordered by the USA’s Federal…

DermatologicalsDermikMergers & AcquisitionsNorth AmericaPharmaceuticalValeant Pharmaceuticals

Valeant to acquire J&J’s Ortho Dermatologics for $345 million

18-07-2011

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says it has signed an…

DermatologicalsJohnson & JohnsonMergers & AcquisitionsOrtho-McNeil-JanssenPharmaceuticalValeant Pharmaceuticals

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top